Risk Factors Update Summary

• Laws in China have evolved, impacting data collection and transfer, requiring approval from authorities.
• Risks associated with Announced Divestitures, including OTC Transaction, could have a material adverse effect.
• Increased use of AI in the pharmaceutical industry poses risks of data disclosure.
• The Company has completed transactions to simplify business, accelerate debt paydown, and unlock shareholder value.
• New regulations in the EU may lead to more stringent reporting requirements.
• The Company may incur losses related to Pending Announced Divestitures, with an estimated pre-tax loss of $735 million.
• Sustainability goals are now company-wide, impacting access, emissions, and shareholder relations.
• The Company's top three customers represented approximately 25% and 26% of net sales in 2023 and 2022, respectively.
• A $1 billion increase in the stock buyback program was announced, totaling $2 billion.
• The Company's sales and marketing efforts are anchored by promoting products to healthcare professionals, clinics, and hospitals.
• A $511 million charge was recorded related to divestitures in 2022 and 2023.
• The Company may face challenges in reducing reliance on transition services, including managing replacement costs.
• The company had approximately $284 million of floating rate debt as of December 31, 2023.
• The Company's top ten products represented approximately 33% of net sales in 2023, impacting demand for products.